Two forms of iron as an intrinsic contrast agent in the basal ganglia of PKAN patients.

Iron deposits in the human brain can be considered as intrinsic contrast agents for magnetic resonance imaging and are used as markers of neurodegeneration accompanied by brain-iron accumulation. We studied one of them - panthotenate-kinase associated neurodegeneration (PKAN) - by using relaxometry at 1.5, 3.0 and 7 T in a group of six patients; we also measured a group of five volunteers for comparison. Based on the magnetic field dependency of antiferromagnetic ferritin and maghemite iron oxide nanoparticle relaxivities, we derived a two-component model for the description of iron deposits in the globus pallidus of PKAN patients. According to this model, we estimated the iron content in PKAN patients as 391 µg/ml of antiferromagnetic iron (ferritin) and 1.1 µg/ml of ferrimagnetic iron, compared with 178 µg/ml of iron in ferritin found in controls. This two-component model explains the nonlinear shape of the relaxometric curves in in vivo measurements of the relaxation rates of PKAN patients and is supported by histological findings in the original reports on PKAN patients.

[1]  A. Gregory,et al.  Pantothenate Kinase-Associated Neurodegeneration , 2013 .

[2]  M. Dezortova,et al.  Changes in the brain during long‐term follow‐up after liver transplantation , 2012, Journal of magnetic resonance imaging : JMRI.

[3]  P. Stoeter,et al.  Missense PANK2 mutation without “Eye of the tiger” sign: MR findings in a large group of patients with pantothenate kinase‐associated neurodegeneration (PKAN) , 2012, Journal of magnetic resonance imaging : JMRI.

[4]  Hui Mao,et al.  Improving the Magnetic Resonance Imaging Contrast and Detection Methods with Engineered Magnetic Nanoparticles , 2012, Theranostics.

[5]  Alessandra Solari,et al.  Iron‐related MRI images in patients with pantothenate kinase–associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial , 2011, Movement disorders : official journal of the Movement Disorder Society.

[6]  F. Micheli,et al.  Pallidal stimulation in siblings with pantothenate kinase‐associated neurodegeneration: Four‐year follow‐up , 2011, Movement disorders : official journal of the Movement Disorder Society.

[7]  D. Jirák,et al.  Magnetic Resonance Imaging of Pancreatic Islets Transplanted Into the Liver in Humans , 2010, Transplantation.

[8]  Michel Luhmer,et al.  Variable-field relaxometry of iron-containing human tissues: a preliminary study. , 2009, Contrast media & molecular imaging.

[9]  F. Jiru,et al.  MR relaxometry and 1H MR spectroscopy for the determination of iron and metabolite concentrations in PKAN patients , 2005, European Radiology.

[10]  R. Muller,et al.  Relaxation induced by ferritin: a better understanding for an improved MRI iron quantification , 2004, NMR in biomedicine.

[11]  A. Roch,et al.  Ferritin‐induced relaxation in tissues: An in vitro study , 2004, Journal of magnetic resonance imaging : JMRI.

[12]  J. Dobson,et al.  Nanoscale biogenic iron oxides and neurodegenerative disease , 2001, FEBS letters.

[13]  A. Roch,et al.  Relaxation induced by ferritin and ferritin‐like magnetic particles: The role of proton exchange , 2000, Magnetic resonance in medicine.

[14]  R A Brooks,et al.  Relaxometry and magnetometry of ferritin , 1998, Magnetic resonance in medicine.

[15]  J. Bulte,et al.  T1 and T2 of ferritin solutions: Effect of loading factor , 1996, Magnetic resonance in medicine.

[16]  David Katz,et al.  The relation between brain iron and NMR relaxation times: An in vitro study , 1996, Magnetic resonance in medicine.

[17]  Rodney A. Brooks,et al.  Magnetic resonance imaging of brain iron in health and disease , 1995, Journal of the Neurological Sciences.

[18]  K F Swaiman,et al.  Hallervorden-Spatz syndrome and brain iron metabolism. , 1991, Archives of neurology.

[19]  S. Kish,et al.  Hallervorden‐Spatz disease: Cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus , 1985, Annals of neurology.

[20]  B. Hallgren,et al.  THE EFFECT OF AGE ON THE NON‐HAEMIN IRON IN THE HUMAN BRAIN , 1958, Journal of neurochemistry.

[21]  J. Hallervorden,et al.  Eigenartige erkrankung im extrapyramidalen system mit besonderer beteiligung des globus pallidus und der substantia nigra , 1922 .

[22]  P. Boesiger,et al.  Age distribution and iron dependency of the T2 relaxation time in the globus pallidus and putamen , 2004, Neuroradiology.

[23]  R Weissleder,et al.  Superparamagnetic iron oxide: pharmacokinetics and toxicity. , 1989, AJR. American journal of roentgenology.